In this issue:
This issue contains a special bonus, but first we take a look at two recent EU court decisions. Kent Bernard, Sean-Paul Brankin, and Kristina Nordlander & Patrick Harrison analyze the (at long last!) judgment on AstraZeneca, raising real concerns about the future of legal protection for IP and R&D. Angela Laghezza contributes some initial insight into the “just-off-the-presses” decision on Akzo and how this will affect in-house counsel privilege. Then we’re providing something extra; a courtesy issue including a dozen articles summarizing the year-to-date in competition policy. Enjoy!
EU Court Decisions: AstraZeneca & Akzo
The AstraZeneca Decision in the General Court: Some Basic Observations and a Few Interesting Questions
The Court reaffirmed two basic principles of EU jurisprudence, put a silver spike through one common argument of the research-based drug industry, and raised some fascinating questions for the future. Kent Bernard (Fordham Law)
The General Court not only upheld the Commission’ novel theories of abuse, it also appears to have extended their potential scope of application. Sean-Paul Brankin (Crowell & Moring)
It seems clear that the Commission will be embol